THERAPY DOSSIER · th-f69e83041ac9

Danaparoid sodium

Drug · Heparinoid mixture of glycosaminoglycans. ChEMBL MoA: antithrombin-III activator; inhibits coagulation by activating antithrombin III, which then binds factor Xa. ATC B01AB09.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Heparinoid mixture of glycosaminoglycans. ChEMBL MoA: antithrombin-III activator; inhibits coagulation by activating antithrombin III, which then binds factor Xa. ATC B01AB09.
Target: CHEMBL1950 (antithrombin-III)
Injury models: Other
Reported indication: Not recorded
First approval: 1996
Development stage: Not recorded
ChEMBL record: CHEMBL1201534 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Danaparoid; Danaparoid sodium; ORG 10172; ORG-10172; Orgaran; Sodium danaparoid
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03809481 ↗PHASE3terminated

Safety and Efficacy of Danaparoid vs Argatroban in Acute Heparin-induced Thrombocytopenia

Heparin-induced Thrombocytopenia

Enrolment: 7 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 20673918 ↗2010Reported benefit

Danaparoid sodium attenuates the effects of heat stress.

RatOtherWistarMaleIntravenous (tail vein)50 U/kgJust prior to heat stress

Model: Heat stress/heat stroke (42 C for 30 min)

Danaparoid sodium pretreatment reduced cytokines and organ damage and improved survival in heat stress.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…